Sk Biopharmaceuticals Co Ltd Market Cap ($4.12 Billion)
Market Cap & Net Worth: Sk Biopharmaceuticals Co Ltd (326030)
Sk Biopharmaceuticals Co Ltd market cap. Sk Biopharmaceuticals Co Ltd (KO:326030) has a market capitalization of $4.12 Billion (₩6.08 Trillion) as of October 31, 2026. Listed on the KO stock exchange, this Korea-based company holds position #3915 globally and #83 in its home market, demonstrating a 3.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Sk Biopharmaceuticals Co Ltd's stock price ₩77700.00 by its total outstanding shares 78313250 (78.31 Million).
Sk Biopharmaceuticals Co Ltd Market Cap History (2020–2026)
Sk Biopharmaceuticals Co Ltd market cap history from 2020 to 2026. Data shows change from $8.97 Billion to $4.12 Billion (-7.47% CAGR). Check 326030 stock price and chart for real-time trading data and today's change.
Sk Biopharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Sk Biopharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see 326030 cash flow metrics for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
0.01x
Sk Biopharmaceuticals Co Ltd's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.02x
Sk Biopharmaceuticals Co Ltd's market cap is 0.02 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $8.97 Billion | $26.00 Billion | -$247.41 Billion | 0.34x | N/A |
| 2021 | $5.16 Billion | $418.64 Billion | $64.85 Billion | 0.01x | 0.08x |
| 2022 | $3.83 Billion | $246.18 Billion | -$139.43 Billion | 0.02x | N/A |
| 2023 | $5.33 Billion | $354.89 Billion | -$32.88 Billion | 0.02x | N/A |
| 2024 | $5.90 Billion | $547.60 Billion | $240.74 Billion | 0.01x | 0.02x |
| 2025 | $6.61 Billion | $706.74 Billion | $266.95 Billion | 0.01x | 0.02x |
Competitor Companies of 326030 by Market Capitalization
Companies near Sk Biopharmaceuticals Co Ltd in the global market cap rankings as of October 31, 2026. See Sk Biopharmaceuticals Co Ltd (326030) balance sheet quality index to understand what proportion of total assets are financed by equity.
Key companies related to Sk Biopharmaceuticals Co Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Sk Biopharmaceuticals Co Ltd (2020–2026)
Market capitalization of Sk Biopharmaceuticals Co Ltd from 2020 to today. Between 2020 and today, Sk Biopharmaceuticals Co Ltd's market cap moved from $8.97 Billion to $ 4.12 Billion, with a yearly change of -7.47%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩4.12 Billion | -37.64% |
| 2025 | ₩6.61 Billion | +12.15% |
| 2024 | ₩5.90 Billion | +10.66% |
| 2023 | ₩5.33 Billion | +39.25% |
| 2022 | ₩3.83 Billion | -25.82% |
| 2021 | ₩5.16 Billion | -42.49% |
| 2020 | ₩8.97 Billion | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Sk Biopharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $4.12 Billion USD |
| MoneyControl | $4.12 Billion USD |
| MarketWatch | $4.12 Billion USD |
| marketcap.company | $4.12 Billion USD |
| Reuters | $4.12 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Sk Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co., Ltd., a pharmaceutical company, engages in the research, development, and commercialization of drugs for the treatment of central nervous system disorders. The company offers Cenobamate, an anti-seizure medication for the treatment of epilepsy and Solriamfetol medication. It develops Carisbamate that is in Phase 3 trials to treat lennox-gastaut syndrome; Relenopride, wh… Read more